|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING EFFECT IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
NEUROMUSCULAR BLOCKING ACTION OF TUBOCURARINE LIKE DRUGS IS ENHANCED
|
CAPREOMYCIN CO-ADMINISTRATION WITH THE DRUG MAY CAUSE INCREASED RISK OF RESPIRATORY PARALYSIS & RENAL DYSFUNCTION
|
INCREASED CHANCES OF PERIPHERAL NEUROPATHY
|
IN VITRO INACTIVATION OF AMINOGLYCOSIDES WHEN RECONSTITUTED WITH UNASYN
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
ANTIHISTAMINES LIKE CHLORPHENIRAMINE MAY MASK THE OTOTOXICITY PRODUCED BY AMINOGLYCOSIDES
|
POTENTIAL FOR INCREASED RISK OF OTOTOXICITY WITH CONCOMITANT THERAPY, ESPECIALLY IN THE PRESENCE OF IMPAIRED RENAL FUNCTION ; AVOID CONCURRENT USE EXCEPT IN PRESENCE OF LIFE THERATENING SITUATIONS
|
AMINOGLYCOSIDES LIKE DRUGS OTOTOXICITY MAY BE MASKED BY THE DRUG
|
PIPERACILLIN CO-ADMINISTRATION MAY RESULT IN SUBSTANTIAL INACTIVATION OF AMINOGLYCOSIDES
|
SYNERGISTIC EFFECT OF INTERFERENCE WITH NERVE TRANSMISSION AT NEUROMUSCULAR JUNCTION WARRENT CAREFUL USE
|
INCREASED RISK OF NEPHROTOXICITY
|
|
|
|
|
|
|
|
|
|
|
|
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
ADDITIVE ACTIVITY OFTEN RESULTS WHEN QUINOLONES ARE COMBINED WITH AMINOGLYCOSIDES
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
INCREASED RISK OF NEPHROTOXICITY & OTOTOXICITY
|
MUCOPOLYSACCHARIDE POLYSULFATE IS INCOMPATIBLE WITH AMINOGLYCOSIDES
|
NEUROMUSCULAR BLOCKING EFFECT OF MAGNESIUM SALT, AMINOGLYCOSIDES & NIFEDEPINE MAY BE ADDITIVE
|
NEUROMUSCULAR BLOCKING EFFECT OF MAGNESIUM SALT, AMINOGLYCOSIDES & NIFEDEPINE MAY BE ADDITIVE
|
NEUROMUSCULAR BLOCKING EFFECT OF MAGNESIUM SALT, AMINOGLYCOSIDES & NIFEDEPINE MAY BE ADDITIVE
|